Join to View Full Profile
1120 15th StAugusta, GA 30912
Phone+1 706-721-2423
Fax+1 706-721-1459
Dr. Kota is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Vamsi Kota is an oncologist in Augusta, GA. He received his medical degree from Armed Forces Medical College Pune and has been in practice 14 years. He is experienced in hematologic oncology, multiple myeloma, and leukemia.
Education & Training
Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2008 - 2011- Medical College of GeorgiaResidency, Internal Medicine, 2004 - 2007
ArMed Forces Medical College PuneClass of 2003
Certifications & Licensure
GA State Medical License 2007 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2016 Oct 01
- Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia Start of enrollment: 2017 Aug 03
- Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 06
- Join now to see all
Publications & Presentations
PubMed
- Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy.Hannah Lust, Liora M Schultz, Soyang Kwon, Gregory W Roloff, Ibrahim Aldoss
Blood Advances. 2025-03-24 - Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.Mark C Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K Waller
Blood Advances. 2025-03-11 - Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.Alexandra E Rojek, Benjamin J McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza
American Journal of Hematology. 2025-03-10
Abstracts/Posters
- Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline UpdatesVamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integr...Vamsi Kota, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Help Desk for Oncologists Treating People with a Rare Leukemia Pays Big DividendsFebruary 2nd, 2023- 'It Was Miraculous:' Cancer Patient First to Get New Immunotherapy at AU Health SystemMay 27th, 2021
Cassie Mitchell: Competing for Team USA in the Paralympic GamesSeptember 7th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
